NCT00427856 2016-07-22
Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
Clinical Trials
8 trialsNCT00405951 2016-07-21
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00407303 2016-07-21
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00682981 2016-07-21
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00521144 2015-05-05
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00438178 2014-05-12
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Completed
NCT00600964 2014-05-12
A Phase I/II Study of GX15-070MS in Untreated CLL
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Completed
NCT00684918 2013-08-26
Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed